Role of erythropoietin receptor expression in malignant melanoma

Journal of Investigative Dermatology

Volumn 130, Issue 1, 2010, Pages 201-210

  Mirmohammadsadegh, Alireza ^a   Marini, Alessandra ^a   Gustrau, Annett ^a   Delia, Dana ^a   Nambiar, Sandeep ^a   Hassan, Mohamed ^a   Hengge, Ulrich R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANEMIA; APOPTOSIS; BIOPSY; CELL MOVEMENT; CELLS, CULTURED; ERYTHROPOIETIN, RECOMBINANT; HUMANS; JANUS KINASE 2; MELANOCYTES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 72049084476     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.162     Document Type: Article

References (49)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K et al. (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565
2. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W, Haroon ZA (2005a) Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 18:421-430 (Pubitemid 40395362)
3. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA (2005b) Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 11:20-27
4. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L et al. (2004) Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3:1525-1532
5. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J et al. (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714
6. Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z et al. (2007) Eythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25:718-722
7. Chen X, Chen Y, Bi Y, Fu N, Shan C, Wang S et al. (2007) Preventive cardioprotection of erythropoietin against doxorubicin-induced cardio-myopathy. Cardiovasc Drugs Ther 21:367-374
8. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM (1996) Expression of erythropoietin by the human placenta. FASEB J 10:760-768
9. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM et al. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107:1892-1895 (Pubitemid 43289368)
10. Fairchild Benyo D, Conrad KP (1999) Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol Reprod 60:861-870
11. Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F et al. (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715 (Pubitemid 32519598)
12. Gong K, Zhang N, Zhang Z, Na Y (2006) Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther 5:582-585
13. Hamadmad SN, Henry MK, Hohl RJ (2008) Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. J Pharmacol Exp Ther 324:1227-1233
14. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12:332-339
15. Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, Tannapfel A et al. (2008) The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene 27:4557-4568
16. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260
17. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ (2008) Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 122:274-280 (Pubitemid 350234712)
18. Jones SS, D'Andrea AD, Haines LL, Wong GG (1990) Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 76:31-35
19. Kim KH, Oudit GY, Backx PH (2008) Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 324:160-169
20. Kirito K, Uchida M, Yamada M, Miura Y, Komatsu N (1997) A distinct function of STAT proteins in erythropoietin signal transduction. J Biol Chem 272:16507-16513
21. Koury MJ, Sawyer ST, Brandt SJ (2002) New insights into erythropoiesis. Curr Opin Hematol 9:93-100
22. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X (2005) Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166:823-830
23. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C et al. (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5:347-355
24. Lee SM, Nguyen TH, Park MH, Kim KS, Cho KJ, Moon DC et al. (2004) EPO receptor-mediated ERK kinase and NF-kappaB activation in erythro-poietin- promoted differentiation of astrocytes. Biochem Biophys Res Commun 320:1087-1095
25. Lester RD, Jo M, Campana WM, Gonias SL (2005) Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280:39273-39277
26. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G et al. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960-5972
27. Li J, Vesey DA, Johnson DW, Gobe G (2007) Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 6:1944-1950
28. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
29. Lopez-Bergami P, Fitchman B, Ronai Z (2008) Understanding signaling cascades in melanoma. Photochem Photobiol 84:289-306
30. Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A et al. (2007) ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 127:2207-2215
31. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S et al. (2006) STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 126:2272-2280
32. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G et al. (2005) Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7:537-543
33. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96:990-996
34. Nambiar S, Mirmohammadsadegh A, Hassan M, Mota R, Marini A, Alaoui A et al. (2007) Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. Carcinogenesis 28:2501-2510
35. Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W (2007) Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43:510-519
36. Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F (2007) Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 9:1122-1129
37. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D et al. (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320
38. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M et al. (2007) Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res 13:4825-4831
39. Sairanen T, Karjalainen-Lindsberg ML, Paetau A, Ijäs P, Lindsberg PJ (2006) Apoptosis dominant in the periinfarct area of human ischaemic stroke-a possible target of antiapoptotic treatments. Brain 129:189-199
40. Schmidt EK, Fichelson S, Feller SM (2004) PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors. BMC Biol 2:7
41. Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H et al. (2000) Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10:421-426
42. Silva M, Grillot D, Benito A, Richard C, Nuñez G, Fernández-Luna JL (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88:1576-1582
43. Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD et al. (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98:1059-1067
44. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110:477-488
45. Van Muijen GN, Cornelissen LM, Jansen CF, Figdor CG, Johnson JP, Bröcker EB et al. (1991) Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 9:259-272
46. Winkelmann JC, Penny LA, Deaven LL, Forget BG, Jenkins RB (1990) The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood 76: 24-30
47. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C et al. (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032
48. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A et al. (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021-1029
49. Yin D, Kawabata H, Tcherniamtchouk O, Huynh T, Black KL, Koeffler HP (2007) Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 31:1193-1198